Bicalutamide combination therapy versus castration alone: A combined analysis of historical data
| Autor: | L. Klotz, Paul F. Schellhammer, K. J. Carroll |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Bicalutamide Combination therapy business.industry Pharmacology medicine.disease Flutamide law.invention Capecitabine chemistry.chemical_compound Prostate cancer chemistry Randomized controlled trial law Internal medicine Multicenter trial Nilutamide medicine business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 22:4634-4634 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2004.22.90140.4634 |
| Popis: | 4634 Background: Meta-analyses of randomized trials using flutamide or nilutamide + castration compared with castration alone in D2 prostate cancer have shown a modest overall survival benefit. No direct comparisons have been undertaken of combination therapy using bicalutamide (‘Casodex’) 50 mg with castration alone; here we combine historical data to try to delineate the likely benefit of bicalutamide in this setting. This methodology has been well accepted in other oncology areas: eg in colon cancer, studies comparing the efficacy of 5-fluorouracil (5-FU) + leucovorin to 5-FU alone, and 5-FU + leucovorin to capecitabine, were integrated on the principle that equivalent groups were being compared in otherwise disparate studies (Stat Med 2003;22:239–64). This analysis resulted in FDA approval for capecitabine based on this approach. Methods: A double-blind, randomized, multicenter trial comparing bicalutamide and flutamide combination therapy (Urology 1997;50:330–6) was combined with the Prostate Cancer ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|